Stock Ratings / Health Care / EIKN / financials

SABS (45) CABA (42) IPSC (28) AGEN (26) ⌘ Pro Terminal →

Eikon Therapeutics Inc. (EIKN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Eikon Therapeutics Inc. (EIKN)?

In FY 2025 (10-K), EIKN converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $8.1M in free cash flow (0.2% FCF margin).

$5.35 -3.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.31

Eikon Therapeutics Inc. (EIKN) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $289.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.31 (-0.81%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EIKN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY EIKN SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$7.47-0.7% Next Q

Q2 (-2Q)

Grade C-$7.42-2.2% Next Q

Q3 (-1Q)

Grade C-$7.26-26.3% Next Q

Current

Grade D$5.35-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EIKN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EIKN currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.59) and Max Pain ($5.62) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EIKN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EIKN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EIKN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$8.1M (0.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	$0	$0	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EIKN)

✓Walkthrough of EIKN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EIKN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.39%▼ SUPPORT BREAKDOWN

2026-10-30O $5.27H $5.40L $5.01C $5.35VOL 552.6K

RES: $15.29SUP: $5.97SMA50: $8.59SMA200: $10.43

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EIKN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EIKN Butterfly Map → + Track EIKN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EIKN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EIKN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EIKN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EIKN)

Health Care Rank #412 of 1016 ⚔️ SABS vs EIKN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EIKN vs. SABS, CABA, IPSC, AGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eikon Therapeutics Inc. (EIKN) ranks #412 by composite RQD confidence (47/100, grade D) and #523 by equity capitalization ($289.8M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EIKN ACTIVE Eikon Therapeutics Inc.	D	47/100	—	—	—	-3.43%	$289.8M	Benchmark Subject
SABS SAB Biotherapeutics Inc.	D	45/100	22.1x	—	-27.4%	+0.94%	$293.9M	/sabs-vs-eikn →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-eikn →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-eikn →
AGEN Agenus Inc.	E	26/100	—	96.0%	-35.0%	-0.56%	$320.2M	/agen-vs-eikn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861123

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EIKN closed FY2025 with $594.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$594.7M	—

3. EIKN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $5.35 (-3.43% 1D, market cap $289.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, EIKN ranks #412 in composite RQD confidence.

How does EIKN compare to SABS and CABA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SABS (SAB Biotherapeutics Inc.) holds a D grade (45/100 RQD, P/E 22.1x, ROIC -27.4%, cap $293.9M) and CABA (Cabaletta Bio Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EIKN?

Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EIKN trading relative to its 50-day, 200-day, and 52-week technical levels?

EIKN last traded at $5.35 (-3.43% on volume of 575,799 shares), positioning the stock -37.72% below its 50-day simple moving average ($8.59) and -48.71% below its 200-day simple moving average ($10.43). Across its 52-week range of $5.01 to $17.40, EIKN sits at the 2.7% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.68 to $6.02).

EIKN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Eikon Therapeutics Inc. (EIKN)?

In FY 2025 (10-K), EIKN converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $8.1M in free cash flow (0.2% FCF margin).

Direct Sub-Reports: EIKN RQD Cockpit EIKN 12M Forecast EIKN Earnings & Move EIKN Dividends & DRIP EIKN Insiders & 13F EIKN Whale Options EIKN Profit Sankey EIKN News & Why